Melane Sampson, Author at BioTuesdays

Developments

eXoZymes selects Curia as CDMO for NCT

eXoZymes (NASDAQ: EXOZ) has entered into an agreement with closely held contract research, development, and manufacturing organization (CDMO) Curia Global to initiate technology transfer and scale-up activities for N...

September 8, 2026

Executive Moves

Chris Benecchi joins Inventiva as COO

Inventiva (Euronext Paris and NASDAQ: IVA) has announced the appointment of biopharmaceutical leader Chris Benecchi as chief operating officer (COO). Mr. Benecchi brings 30 years of biopharmaceutical leadership across...

September 2, 2026

Developments

Polyrizon completes site contracts for NASARIX first-in-human allergy study

Polyrizon (NASDAQ: PLRZ) has completed contracting with the fourth and fifth U.S. clinical sites participating in its study of NASARIX Allergy Blocker (PL-14), moving the program into study execution. The planned first...

September 2, 2026

Developments

cbdMD to acquire Twinlab brands

cbdMD (NYSE American: YCBD) has announced that it has entered into a definitive asset purchase agreement to acquire operating assets and brands of Twinlab, including Twinlab, Reserveage, Metabolife, and Alvita Tea...

September 2, 2026

Developments

USPTO issues NOA for Purple’s next-gen multispecific antibody platform

Purple Biotech (NASDAQ/TASE: PPBT) has announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance (NOA) for a patent application covering tri-specific antibody constructs and methods of use...

September 2, 2026

Developments

Valion announces changes to management and BOD

Valion Bio (NASDAQ: VBIO) has announced that its current chief financial officer, Lisa Wolf, has also been named president and chief operating officer, effective immediately, following the departure of former chief...

September 1, 2026

Developments

Profound strengthens leadership team with appointment of Richard Fabian as president

Profound Medical (NASDAQ: PROF; TSX: PRN) has appointed Richard Fabian as president, effective immediately, succeeding Mathieu Burtnyk, PhD, who has assumed the newly created position of chief technology officer. Mr...

September 1, 2026

Feature

electroCore builds on its neuromodulation platform to drive its next phase of growth

electroCore (NASDAQ: ECOR) has built a commercial-stage bioelectric medicine and wellness platform around non-invasive neuromodulation, with applications spanning prescription therapeutics, military human performance...

September 1, 2026

Developments

TELA announces COO/CFO transition and cost reduction

TELA Bio (NASDAQ: TELA) has announced that Roberto Cuca, chief operating officer and chief financial officer (COO/CFO), will step down from the role effective today. In a statement, Heather Getz, CEO of TELA, commented...

August 31, 2026

Developments

Aprea announces IP expansion for precision oncology programs

Aprea Therapeutics (NASDAQ: APRE) has announced an expansion of its intellectual property (IP) portfolio for precision oncology programs. According to Aprea, the company has strengthened its global IP portfolio with 28...

August 28, 2026

Author - Melane Sampson

eXoZymes selects Curia as CDMO for NCT

Chris Benecchi joins Inventiva as COO

Polyrizon completes site contracts for NASARIX first-in-human allergy study

cbdMD to acquire Twinlab brands

USPTO issues NOA for Purple’s next-gen multispecific antibody platform

Valion announces changes to management and BOD

Profound strengthens leadership team with appointment of Richard Fabian as president

electroCore builds on its neuromodulation platform to drive its next phase of growth

TELA announces COO/CFO transition and cost reduction

Aprea announces IP expansion for precision oncology programs

Subscribe